Brian M Zeglis

List of Publications by Year
in descending order

71	3,992	109321 35	118850 62
papers	citations	h-index	g-index

73	73	73	3881
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Impact of Tyrosine Iodination on the Aggregation and Cleavage Kinetics of MMP-9-Responsive Peptide Sequences. ACS Biomaterials Science and Engineering, 2022, 8, 579-587.	5.2	8
2	ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Clinical Cancer Research, 2022, 28, 948-959.	7.0	11
3	Pretargeted PET of Osteodestructive Lesions in Dogs. Molecular Pharmaceutics, 2022, 19, 3153-3162.	4.6	10
4	On the consensus nomenclature rules for radiopharmaceutical chemistry â€“ Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
5	Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics, 2021, 18, 338-346.	4.6	6
6	A Theranostic Cellulose Nanocrystalâ€Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small, 2021, 17, e2007705.	10.0	24
7	Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry, 2021, 32, 1255-1262.	3.6	7
8	Harnessing PET to track micro- and nanoplastics in vivo. Scientific Reports, 2021, 11, 11463.	3.3	24
9	Inverse electron demand Dielsâ€“Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. Nature Protocols, 2021, 16, 3348-3381.	12.0	19
10	DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages. Bioconjugate Chemistry, 2020, 31, 2789-2806.	3.6	14
11	Harnessing ⁶⁴ Cu/ ⁶⁷ Cu for a theranostic approach to pretargeted radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28316-28327.	7.1	67
12	89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe. Molecules, 2020, 25, 2315.	3.8	6
13	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology, 2020, 296, 370-378.	7.3	40
14	Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Frontiers in Pharmacology, 2020, 11, 170.	3.5	57
15	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. Molecular Pharmaceutics, 2020, 17, 3140-3147.	4.6	10
16	Manipulating the In Vivo Behaviour of 68Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance. International Journal of Molecular Sciences, 2020, 21, 1496.	4.1	10
17	The Influence of Glycans-Specific Bioconjugation on the FcÎ³RI Binding and In vivo Performance of ⁸⁹Zr-DFO-Pertuzumab. Theranostics, 2020, 10, 1746-1757.	10.0	31
18	Removal of Fc Glycans from [⁸⁹Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8⁺ T Cells. Molecular Pharmaceutics, 2020, 17, 2099-2108.	4.6	5

#	Article	IF	Citations
19	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2881.	7.0	69
20	Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept. Theranostics, 2019, 9, 6706-6718.	10.0	23
21	Dual Radionuclide Theranostic Pretargeting. Molecular Pharmaceutics, 2019, 16, 4416-4421.	4.6	33
22	A brief overview of metal complexes as nuclear imaging agents. Dalton Transactions, 2019, 48, 14547-14565.	3.3	26
23	Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction. Journal of Visualized Experiments, 2019, , .	0.3	7
24	Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates. Journal of Visualized Experiments, 2019, , .	0.3	5
25	Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics, 2019, 16, 2259-2263.	4.6	19
26	The Impact of FcÎ³RI Binding on Immuno-PET. Journal of Nuclear Medicine, 2019, 60, 1174-1182.	5.0	37
27	Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 868-880.	7.0	55
28	Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability. Bioconjugate Chemistry, 2018, 29, 1364-1372.	3.6	29
29	Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. Molecular Pharmaceutics, 2018, 15, 1729-1734.	4.6	36
30	Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 672-692.	1.0	26
31	The inverse electron-demand Dielsâ€“Alder reaction as a new methodology for the synthesis of225Ac-labelled radioimmunoconjugates. Chemical Communications, 2018, 54, 2599-2602.	4.1	33
32	Site-Specifically Labeled Antibodyâ€“Drug Conjugate for Simultaneous Therapy and ImmunoPET. Molecular Pharmaceutics, 2018, 15, 892-898.	4.6	38
33	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Research, 2018, 78, 1820-1832.	0.9	69
34	PARP-1â€“Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	5.0	51
35	First-in-Human Human Epidermal Growth Factor Receptor 2â€“Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 900-906.	5.0	126
36	Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations. Bioconjugate Chemistry, 2018, 29, 2734-2740.	3.6	28

#	Article	IF	Citations
37	Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics, 2017, 16, 124-133.	4.1	79
38	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research, 2017, 77, 3931-3941.	0.9	91
39	A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. Journal of Visualized Experiments, 2017, , .	0.3	0
40	Exploring Structural Parameters for Pretargeting Radioligand Optimization. Journal of Medicinal Chemistry, 2017, 60, 8201-8217.	6.4	52
41	Pretargeted Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 1553-1559.	5.0	143
42	ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. Molecular Imaging and Biology, 2017, 19, 325-327.	2.6	0
43	Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. EJNMMI Research, 2017, 7, 95.	2.5	58
44	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. Theranostics, 2016, 6, 2267-2277.	10.0	53
45	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Bioconjugate Chemistry, 2016, 27, 1789-1795.	3.6	60
46	Molecular Imaging of Ovarian Cancer. Journal of Nuclear Medicine, 2016, 57, 827-833.	5.0	17
47	A Bone-Seeking trans-Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using ^{99m}Tc- and ¹⁷⁷Lu-Labeled Tetrazines. Journal of Medicinal Chemistry, 2016, 59, 9381-9389.	6.4	41
48	Nearâ€Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem, 2016, 11, 1978-1982.	3.2	5
49	A comparative evaluation of the chelators H 4 octapa and CHX-Aâ€³-DTPA with the therapeutic radiometal 90 Y. Nuclear Medicine and Biology, 2016, 43, 566-576.	0.6	25
50	Click Chemistry and Radiochemistry: The First 10 Years. Bioconjugate Chemistry, 2016, 27, 2791-2807.	3.6	197
51	Site-Specifically Labeled Immunoconjugates for Molecular Imagingâ€"Part 1: Cysteine Residues and Glycans. Molecular Imaging and Biology, 2016, 18, 1-17.	2.6	101
52	Site-Specifically Labeled Immunoconjugates for Molecular Imagingâ€"Part 2: Peptide Tags and Unnatural Amino Acids. Molecular Imaging and Biology, 2016, 18, 153-165.	2.6	60
53	Preclinical ⁸⁹Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. Journal of Nuclear Medicine, 2016, 57, 771-776.	5.0	31
54	¹⁸F-Based Pretargeted PET Imaging Based on Bioorthogonal Dielsâ€"Alder Click Chemistry. Bioconjugate Chemistry, 2016, 27, 298-301.	3.6	127

#	Article	IF	Citations
55	Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. Journal of Nuclear Medicine, 2016, 57, 453-459.	5.0	80
56	Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging. Journal of Visualized Experiments, 2015, , e52335.	0.3	6
57	Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15850-15855.	7.1	85
58	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. Molecular Pharmaceutics, 2015, 12, 3575-3587.	4.6	88
59	The Bioconjugation and Radiosynthesis of ⁸⁹Zr-DFO-labeled Antibodies. Journal of Visualized Experiments, 2015, , .	0.3	60
60	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solidâ€Phase Peptide Synthesis. ChemistryOpen, 2014, 3, 48-53.	1.9	24
61	Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging. Bioconjugate Chemistry, 2014, 25, 2123-2128.	3.6	64
62	The inverse electron demand Dielsâ€“Alder click reaction in radiochemistry. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 285-290.	1.0	53
63	Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals. Inorganic Chemistry, 2014, 53, 1880-1899.	4.0	75
64	Synthesis and evaluation of 18F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. European Journal of Medicinal Chemistry, 2014, 86, 769-781.	5.5	9
65	PET imaging with 89Zr: From radiochemistry to the clinic. Nuclear Medicine and Biology, 2013, 40, 3-14.	0.6	338
66	Enzyme-Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry. Bioconjugate Chemistry, 2013, 24, 1057-1067.	3.6	123
67	A Pretargeted PET Imaging Strategy Based on Bioorthogonal Dielsâ€“Alder Click Chemistry. Journal of Nuclear Medicine, 2013, 54, 1389-1396.	5.0	247
68	Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Dielsâ€“Alder Click Chemistry. Bioconjugate Chemistry, 2011, 22, 2048-2059.	3.6	142
69	Role of Metalation in the Topoisomerase IIÎ± Inhibition and Antiproliferation Activity of a Series of Î±-Heterocyclic-N‹sup›4‹/sup›-Substituted Thiosemicarbazones and Their Cu(II) Complexes. Journal of Medicinal Chemistry, 2011, 54, 2391-2398.	6.4	168
70	A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Transactions, 2011, 40, 6168.	3.3	169
71	The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nuclear Medicine and Biology, 2011, 38, 683-696.	0.6	18